RU97113497A - APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF GYNECOLOGICAL DISEASES - Google Patents

Claims (1)

1. The use of compounds of General formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing gynecological diseases. 2. The use according to claim 1 of compounds of general formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing endometriosis. 3. The use according to claim 1 of compounds of the general formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing dysfunctional bleeding. 4. The use according to claim 1 of compounds of general formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing endometrial cancer. 5. The use according to claim 1 of compounds of general formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing polycystic ovarian syndrome. 6. The use according to claim 1 of compounds of general formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing anovulatory bleeding. 7. The use of compounds of General formula I

in which R1, R4 and R5 each individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R2 and R3 are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for thinning the endometrium.  8. The use according to any one of paragraphs. 1-7, in which R1 in the compound used is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.  9. The use according to any one of paragraphs. 1-8, in which R1 represents methoxy.  10. The use according to any one of paragraphs. 1-9, in which R2 represents methyl.  11. The use according to any one of paragraphs. 1-10, in which R3 represents methyl.  12. The use according to any one of paragraphs. 1-11, in which R4 represents hydrogen. 13. The use according to any one of paragraphs. 1-12, in which R5 represents a group, as indicated in formula II below:

14. The use according to any one of paragraphs. 1-13, in which the specified connection is an isolated d - or l-enantiomer. 15. The use according to any one of paragraphs. 1-14, in which the specified connection has the General formula III, as indicated below:

and the substituents are as defined in paragraph 1 above.  16. The use according to any one of the preceding claims, wherein said compound is an isolated l-enantiomer. 17. The use according to any one of paragraphs. 1-15, in which the specified connection is Centroman, having the formula IV, as indicated below:

18. The use according to claim 17, wherein said compound is an isolated d- or l-enantiomer.  19. The use according to claim 17, wherein said compound is an isolated l-enantiomer.  20. The use according to any one of paragraphs. 1-19, in which the specified composition is in a form suitable for oral administration.  21. The use according to any one of paragraphs. 1-20, in which the specified compound is administered in a dose in the range from approximately 0.001 to 75, preferably in the range from approximately 0.01 to 75, more preferably in the range from approximately 0.01 to 50 and especially in the range from approximately 0.1 up to 25 mg / kg patient weight per day.  22. The use according to any one of paragraphs. 1-21, in which the specified connection is administered one or more times a day or week.  23. The use according to any one of paragraphs. 1-21, in which the specified composition is in the form of a dermal implant.  24. A method of treating and preventing endometriosis, comprising administering to a patient a therapeutically effective amount of a compound of formula I, as claimed in claim 1, claimed for use at any of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent endometriosis.  25. A method of treating and preventing dysfunctional bleeding, comprising administering to a patient a therapeutically effective amount of a compound of formula I, as claimed for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent dysfunctional bleeding.  26. A method for the treatment and prevention of endometrial cancer, comprising administering to the patient a therapeutically effective amount of a compound of formula I, stated for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent endometrial cancer.  27. A method of treating and preventing polycystic ovarian syndrome, comprising administering to a patient a therapeutically effective amount of a compound of formula I declared for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat or prevent polycystic ovarian syndrome.  28. A method of treating and preventing anovulatory hemorrhage, comprising administering to a patient a therapeutically effective amount of a compound of formula I declared for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent anovulatory hemorrhage.  29. A method of thinning the endometrium, comprising administering to a patient a therapeutically effective amount of a compound of formula I, as claimed for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof.  30. A method of treating or preventing endometriosis, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  31. A method of treating or preventing dysfunctional bleeding, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  32. A method for treating or preventing endometrial cancer, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  33. A method of treating or preventing polycystic ovarian syndrome, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  34. A method of treating or preventing anovulatory hemorrhage, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  35. A method for thinning the endometrium, the method comprising administering a therapeutically effective amount of the compounds and pharmaceutically acceptable compositions of the preceding paragraphs to a patient in need of such treatment.  36. Any new feature or combination of features described here.